Free Trial
→ Today's free pick (on me) (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$283.69
+1.2%		$266.83
$193.45
▼
$286.08
$675.03B0.227.50 million shs8.80 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$19.31
$18.44
$14.06
▼
$20.13
$37.09B0.4818.80 million shsN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$134.38
-0.4%		$140.65
$77.00
▼
$160.81
$8.80B1.21622,367 shs542,889 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.13%+4.11%+13.98%+8.93%+45.84%
Kenvue Inc. stock logo
KVUE
Kenvue
0.00%0.00%+8.82%+0.60%+15.58%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-0.36%-0.65%-2.97%-13.36%+58.37%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$283.69
+1.2%		$266.83
$193.45
▼
$286.08
$675.03B0.227.50 million shs8.80 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$19.31
$18.44
$14.06
▼
$20.13
$37.09B0.4818.80 million shsN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$134.38
-0.4%		$140.65
$77.00
▼
$160.81
$8.80B1.21622,367 shs542,889 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.13%+4.11%+13.98%+8.93%+45.84%
Kenvue Inc. stock logo
KVUE
Kenvue
0.00%0.00%+8.82%+0.60%+15.58%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-0.36%-0.65%-2.97%-13.36%+58.37%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$275.92-2.74% Downside
Kenvue Inc. stock logo
KVUE
Kenvue
2.00
Hold$19.29-0.13% Downside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.06
Buy$166.6724.03% Upside

Current Analyst Ratings Breakdown

Latest JNJ, PTGX, and KVUE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform
11/6/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$170.00 ➝ $221.00
11/4/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C+) ➝ Buy (B-)
11/3/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
11/2/2026
Kenvue Inc. stock logo
KVUE
Kenvue
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$19.00 ➝ $20.00
10/23/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy (B+) ➝ Buy (B-)
10/23/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy (B-) ➝ Hold (C+)
10/21/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$155.00 ➝ $160.00
10/21/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Johnson Rice logo
Johnson Rice
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold
10/21/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Erste Group Bank AG logo
Erste Group Bank
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold
10/20/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$300.00
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B7.25$14.28 per share19.86$33.87 per share8.38
Kenvue Inc. stock logo
KVUE
Kenvue
$15.53B2.39$1.38 per share14.02$5.62 per share3.44
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$46.02M190.59N/AN/A$16.62 per share8.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$6.6042.9824.542.7716.20%31.64%13.04%1/26/2027 (Estimated)
Kenvue Inc. stock logo
KVUE
Kenvue
$1.47B$0.8821.9415.831.7710.76%21.22%8.37%N/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$130.15M$4.7228.57101.04N/A62.04%42.83%40.29%N/A

Latest JNJ, PTGX, and KVUE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$2.50$3.07+$0.57$3.07$238.49 million$274.41 million
10/30/2026Q3 2026
Kenvue Inc. stock logo
KVUE
Kenvue
$0.2915$0.29-$0.0015$0.22$3.86 billion$3.89 billion
10/13/2026Q3 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.53$2.59+$0.06$0.09$25.38 billion$25.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.361.89%+5.25%81.21%64 Years
Kenvue Inc. stock logo
KVUE
Kenvue
$0.844.35%N/A95.45%1 Years
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A

Latest JNJ, PTGX, and KVUE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.15%11/24/202611/24/202612/8/2026
9/10/2026
Kenvue Inc. stock logo
KVUE
Kenvue
quarterly$0.214.75%9/21/20269/21/202610/2/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.02
0.74
Kenvue Inc. stock logo
KVUE
Kenvue
0.67
1.01
0.71
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
19.85
21.71

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Kenvue Inc. stock logo
KVUE
Kenvue
97.64%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Kenvue Inc. stock logo
KVUE
Kenvue
1.59%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
5.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Kenvue Inc. stock logo
KVUE
Kenvue
22,0001.92 billion1.89 billionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
14165.27 million61.88 millionOptionable

Recent News About These Companies

Protagonist Therapeutics, Inc. $PTGX Stock Holdings Trimmed by Nan Fung Trinity HK Ltd.
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-protagonist-therapeutics-inc-ptgx-stock-holdings-trimmed-by-nan-fung-trinity-hk-ltd-2026-11-13/
HC Wainwright Has Optimistic Opinion of PTGX FY2026 Earnings
November 12 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31192970
HC Wainwright Has Bullish Outlook for PTGX FY2026 Earnings
November 10 at 6:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-has-bullish-outlook-for-ptgx-fy2026-earnings-2026-11-10/
Protagonist Therapeutics, Inc. $PTGX Stock: Pictet Asset Management Holding SA Lowers Stake
November 10 at 5:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-protagonist-therapeutics-inc-ptgx-stock-pictet-asset-management-holding-sa-lowers-stake-2026-11-10/
Protagonist Therapeutics, Inc. $PTGX Shares Sold by State of Wyoming
November 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-protagonist-therapeutics-inc-ptgx-shares-sold-by-state-of-wyoming-2026-11-09/
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $221.00
November 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31187544
J&J posts late-stage trial win for plaque psoriasis pill in psoriatic arthritis
November 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4668722-jj-posts-trial-win-psoriatic-arthritis-pill
Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at Wall Street Zen
November 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31183495
Wall Street Zen Upgrades Protagonist Therapeutics (NASDAQ:PTGX) to "Strong-Buy"
November 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-upgrades-protagonist-therapeutics-nasdaq-ptgx-to-strong-buy-2026-11-07/
Protagonist Therapeutics (NASDAQ:PTGX) Announces Earnings Results, Beats Estimates By $0.57 EPS
November 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/earnings-protagonist-therapeutics-nasdaq-ptgx-announces-earnings-results-beats-estimates-by-057-eps-2026-11-06/
Protagonist Therapeutics (PTGX) Stock Looks Priced At A Premium As Its 7x Three Year Run Continues
November 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/protagonist-therapeutics-ptgx-stock-looks-171504078.html
HC Wainwright Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock
November 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hc-wainwright-forecasts-strong-price-appreciation-for-protagonist-therapeutics-nasdaq-ptgx-stock-2026-11-06/
Protagonist Therapeutics (PTGX) Swung To Profit, Is It A Bargain Or Fully Priced?
November 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/protagonist-therapeutics-ptgx-swung-profit-111315472.html
Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates
November 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3024868/protagonist-therapeutics-ptgx-q3-earnings-and-revenues-surpass-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-3024868
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 5, 2026  |  oklahoman.comO
Protagonist Therapeutics (NASDAQ:PTGX) Shares Break Above 50 Day Moving Average - Should You Sell?
November 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-protagonist-therapeutics-nasdaq-ptgx-shares-break-above-50-day-moving-average-should-you-sell-2026-11-05/
Protagonist Therapeutics stock: Four November conferences announced
October 29, 2026  |  ad-hoc-news.deA
Why Protagonist Therapeutics (PTGX) is a top momentum stock for the long term
October 29, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/why-protagonist-therapeutics-ptgx-is-a-top-momentum-stock-for-the-long-term/ar-AA2gl9Jf
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
October 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3018614/protagonist-therapeutics-ptgx-to-report-q3-results-wall-street-expects-earnings-growth?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_9-3018614
Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term
October 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3018395/why-protagonist-therapeutics-ptgx-is-a-top-momentum-stock-for-the-long-term?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_momentum_score-3018395
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Moody Aldrich Partners LLC
October 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-protagonist-therapeutics-inc-ptgx-shares-sold-by-moody-aldrich-partners-llc-2026-10-29/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$283.69 +3.28 (+1.17%)
Closing price 11/12/2026 03:59 PM Eastern
Extended Trading
$284.18 +0.50 (+0.17%)
As of 06:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Kenvue stock logo

Kenvue NYSE:KVUE

$19.31 0.00 (0.00%)
As of 11/6/2026

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$134.38 -0.48 (-0.36%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$132.84 -1.54 (-1.15%)
As of 04:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas